Krystal Biotech Hits New 52-Week High of $347.67, Up 93%

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 347.67 on June 17, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 93.21%, significantly outpacing the S&P 500's growth of 24.03% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor sentiment regarding its earnings potential. Additionally, the company maintains a return on equity of 16.80%, showcasing its efficiency in generating profits from shareholders' equity. With a price-to-book ratio of 5.88 and a debt-to-equity ratio of -0.68, Krystal Biotech demonstrates a solid financial foundation. The stock's previous 52-week low was recorded at USD 127.99, highlighting the significant upward trajectory it has experienced. This new high marks a pivotal moment for the company as it continues to navigate the competitive landscape of the biotechnology industry.